ASGCT 2021 International Forum

Building next generation engineered cell medicines – Leveraging the benefits of non-viral transfection in increasingly complex product development

Abstract

Tuesday, May 11 2021

Building next generation engineered cell medicines – Leveraging the benefits of non-viral transfection in increasingly complex product development.
As therapeutic product developers move toward novel and highly engineered cell therapy constructs, the importance of a versatile, consistent, and scalable platform that bypasses the limitations and safety concerns associated with viral transduction is critical. With an expanding variety of target cell types and increasing engineering complexity, effective product development requires a technology readily adaptable to varying workflows – different cell types and payloads, unique engineering and process development, while maintaining high cell viability, phenotype and quality through scale up. This Industry Symposium brings together leaders in the cell therapy arena to present and discuss latest advances across a spectrum of indications and therapeutic approaches.

Panel Moderator:

Sarah Haecker Meeks, PhD

Title/Role:  Vice President, Business Development
Organization:  MaxCyte, Inc.

Panelists

Daniel Getts, PhD

Title/Role: Chief Executive Officer
Organization: Myeloid Therapeutics

James Trager, PhD

Title/Role: Chief Scientific Officer
Organization: NKARTA Therapeutics

Julia Berretta

Title/Role: Chief Executive Officer
Organization: Genespire

John Tisdale, MD

Title/Role: Senior Investigator and Director
Organization: NIH/NHLBI

Sadik Kassim, PhD

Title/Role: Chief Technology Officer
Organization: VOR Biopharma

Visit our posters in the poster hall

Electroporation of a Non-Integrative DNA Nanovector for Efficient, Semi-Automated, GMP Manufacturing of CAR T Cell Therapies and the image both attached.